In8Bio (INAB) Total Liabilities (2020 - 2026)
In8Bio (INAB) posted Total Liabilities of $3.5 million for Q1 2026, down 26.25% sequentially from $4.7 million in Q4 2025, and down 41.86% YoY from $6.0 million in Q1 2025.
In8Bio (INAB) Total Liabilities (2020 - 2026) Analysis & Trends
In8Bio has reported Total Liabilities for 7 years, with the latest figure at $3.5 million in Q1 2026.
- Quarterly Total Liabilities fell 41.86% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 41.86% YoY) and the FY2025 annual result came in at $4.7 million, down 26.94% from the prior year.
- Total Liabilities slipped to $3.5 million in Q1 2026 per INAB's latest filing, from $4.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $10.3 million in Q4 2022 and troughed at $3.5 million in Q1 2026.
- A 5-year average of $6.6 million and a median of $6.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 155.12% in 2022, then plunged 53.44% in 2025.
- Over 5 years, Total Liabilities stood at $10.3 million in 2022, then declined by 14.89% to $8.8 million in 2023, then slipped by 26.29% to $6.5 million in 2024, then slipped by 26.94% to $4.7 million in 2025, then dropped by 26.25% to $3.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $3.5 million, $4.7 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Mn |
| Mar 31, 2026 | 3.48 Mn |
| Dec 31, 2025 | 4.72 Mn |
| Sep 30, 2025 | 3.58 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 5.99 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | 7.38 Mn |
| Jun 30, 2024 | 8.88 Mn |
| Dec 31, 2023 | 8.77 Mn |
| Sep 30, 2023 | 8.45 Mn |
| Jun 30, 2023 | 7.92 Mn |
| Mar 31, 2023 | 7.89 Mn |
| Dec 31, 2022 | 10.31 Mn |
| Sep 30, 2022 | 8.82 Mn |
| Jun 30, 2022 | 4.42 Mn |
| Mar 31, 2022 | 3.70 Mn |
| Dec 31, 2021 | 4.04 Mn |
| Sep 30, 2021 | 4.10 Mn |
| Jun 30, 2021 | 3.90 Mn |